Parmax Pharma Ltd (PARMAX) — shareholding pattern, promoter holding, financials and share price
About Parmax Pharma Ltd (PARMAX)
Parmax Pharma Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as PARMAX and on the BSE under scrip code 540359. Its ISIN is INE240T01014.
Incorporated in 1994, Parmax Pharma Ltd manufactures Bulk Drugs, Drug Intermediates & Speciality Chemicals. [1]
Parmax Pharma Ltd, established in 1994, focuses on Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations (CMO).
The company initially manufactured antibiotics and speciality chemicals but discontinued business activities for some years before focusing on the current pharmaceutical operations.
Listed peers in Pharmaceuticals: Lasa Supergenerics Ltd, Roopa Industries Ltd, JFL Life Sciences Ltd, Medi Caps Ltd, Walpar Nutritions Ltd, Welcure Drugs & Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹91.49 a share on 10 Jul 2026, Parmax Pharma Ltd (PARMAX) was valued at a price-to-earnings ratio of -8.25x against an industry P/E of 36.41x. Solomo computes return on equity of 67.65% and return on capital employed of -79.44% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -8.25x
- Industry P/E
- 36.41x
- EPS (TTM)
- ₹-11.09
- Book value / share
- ₹-5.32
- ROE
- 67.65%
- ROCE
- -79.44%
- ROA
- -22.13%
- Debt / equity
- -1.87x
- Dividend yield
- 0%
- EBITDA margin
- -29.15%
- 52-week range
- ₹22.6 – ₹91.48
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Parmax Pharma Ltd (PARMAX) reported revenue of ₹12.11 crore, net profit of ₹-4.16 crore and earnings per share of ₹-11.12. That compares with revenue of ₹28.2 crore and net profit of ₹-2.09 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹3.31 crore and net profit ₹-0.58 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 18.24 | 15.39 | 11.02 | 28.2 | 12.11 |
| Net profit (₹ cr) | 0.14 | -0.1 | -5.75 | -2.09 | -4.16 |
| EPS (₹) | 0.37 | -0.27 | -15.37 | -5.59 | -11.12 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 6.14% | 15.61% | 155.20% |
| Profit growth | - | - | 63.65% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 30.8% of Parmax Pharma Ltd (PARMAX) (unchanged from the previous quarter). Market capitalisation was ₹34 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2016.
Largest disclosed public shareholders in Jun 2026: GOSALIA MEENA ALKESH 12.69%, ABHAY CHINUBHAI SHAH 6.59%, UMANG ALKESH GOSALIA 5.35%, GOSALIA NIMIT P 2.4%, RUPA SUNIL SHAH 1.43%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 30.8% | - | - | - | 69.2% |
| Mar 2026 | 30.8% | - | - | - | 69.2% |
| Dec 2025 | 30.8% | - | - | - | 69.2% |
| Sep 2025 | 30.8% | - | - | - | 69.2% |
| Jun 2025 | 30.8% | - | - | - | 69.2% |
| Mar 2025 | 30.8% | - | - | - | 69.2% |
| Dec 2024 | 30.8% | - | - | - | 69.2% |
| Sep 2024 | 30.8% | - | - | - | 69.2% |